Oppenheimer & CO Inc Harrow Health, Inc. Transaction History
Oppenheimer & CO Inc
- $7.83 Billion
- Q3 2025
A detailed history of Oppenheimer & CO Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 14,994 shares of HROW stock, worth $610,855. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,994
Previous 13,317
12.59%
Holding current value
$610,855
Previous $406,000
73.89%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding HROW
# of Institutions
218Shares Held
21.7MCall Options Held
998KPut Options Held
593K-
Opaleye Management Inc. Boston, MA3.91MShares$159 Million30.67% of portfolio
-
Black Rock Inc. New York, NY2.15MShares$87.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.87MShares$76.2 Million0.0% of portfolio
-
Private Capital Management, LLC Naples, FL1.86MShares$75.6 Million9.42% of portfolio
-
State Street Corp Boston, MA794KShares$32.4 Million0.0% of portfolio
About HARROW HEALTH, INC.
- Ticker HROW
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 27,070,000
- Market Cap $1.1B
- Description
- Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...